BIOMAT Database Logo BIOMAT Database Logo

Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. 1988

P J Martin, and J A Hansen, and B Torok-Storb, and D Durnam, and D Przepiorka, and J O'Quigley, and J Sanders, and K M Sullivan, and R P Witherspoon, and H J Deeg
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98104.

Results of a previous study suggested that the risk of graft failure after transplantation of HLA-identical T cell-depleted marrow may be influenced by the preparative regimen. Subsequent clinical trials were carried out to clarify this relationship and to determine whether post-transplant immunosuppression could have an effect on graft durability. Two factors were found to be associated with graft failure. Patients with hematologic malignancy given a preparative regimen of cyclophosphamide (120 mg/kg) and 15.75 Gy fractionated total body irradiation (TBI) had a 27% cumulative incidence of graft failure, which was less than the 69% incidence seen previously in patients given cyclophosphamide and 12.0 Gy fractionated TBI (p less than 0.05, log-rank test). Patients with acute leukemia had a higher risk of graft failure than patients with chronic myelogenous leukemia (p less than 0.005). The incidence of graft failure was not influenced by post-transplant immunosuppression with cyclosporine, methotrexate or a combination of cyclosporine plus methotrexate or by the omission of all post-transplant immunosuppression. Similarly, graft failure was not associated with the complement lot used for marrow treatment, the recovery of BFU-E or CFU-GM, or with the number of nucleated cells or T cells in the graft. The effect of primary diagnosis and the inverse relationship between the amount of pretransplant TBI and the graft failure rate suggest that a host factor may have been involved in a presumably immune-mediated rejection. This observation further leads to the inference that certain T cells present in donor marrow can suppress host immunity or help to maintain function of the graft.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008212 Lymphocyte Depletion Immunosuppression by reduction of circulating lymphocytes or by T-cell depletion of bone marrow. The former may be accomplished in vivo by thoracic duct drainage or administration of antilymphocyte serum. The latter is performed ex vivo on bone marrow before its transplantation. Depletion, Lymphocyte
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013601 T-Lymphocytes Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen. T Cell,T Lymphocyte,T-Cells,Thymus-Dependent Lymphocytes,Cell, T,Cells, T,Lymphocyte, T,Lymphocyte, Thymus-Dependent,Lymphocytes, T,Lymphocytes, Thymus-Dependent,T Cells,T Lymphocytes,T-Cell,T-Lymphocyte,Thymus Dependent Lymphocytes,Thymus-Dependent Lymphocyte
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting

Related Publications

P J Martin, and J A Hansen, and B Torok-Storb, and D Durnam, and D Przepiorka, and J O'Quigley, and J Sanders, and K M Sullivan, and R P Witherspoon, and H J Deeg
Graft failure after T cell depleted HLA identical allogeneic bone marrow transplantation: risk factors in leukemic patients.
November 1993, Leukemia & lymphoma,
P J Martin, and J A Hansen, and B Torok-Storb, and D Durnam, and D Przepiorka, and J O'Quigley, and J Sanders, and K M Sullivan, and R P Witherspoon, and H J Deeg
Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow.
January 1991, Bone marrow transplantation,
P J Martin, and J A Hansen, and B Torok-Storb, and D Durnam, and D Przepiorka, and J O'Quigley, and J Sanders, and K M Sullivan, and R P Witherspoon, and H J Deeg
Graft-versus-host disease in children receiving HLA-identical allogeneic bone marrow transplants with a low adjusted T lymphocyte dose.
November 1991, Bone marrow transplantation,
P J Martin, and J A Hansen, and B Torok-Storb, and D Durnam, and D Przepiorka, and J O'Quigley, and J Sanders, and K M Sullivan, and R P Witherspoon, and H J Deeg
Hyperfractionated total body irradiation for T-depleted HLA identical bone marrow transplants.
February 1988, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,
P J Martin, and J A Hansen, and B Torok-Storb, and D Durnam, and D Przepiorka, and J O'Quigley, and J Sanders, and K M Sullivan, and R P Witherspoon, and H J Deeg
Successful graft-versus-host disease prevention without graft failure in 32 HLA-identical allogeneic bone marrow transplantations with marrow depleted of T cells by monoclonal antibodies and complement.
February 1987, Blood,
P J Martin, and J A Hansen, and B Torok-Storb, and D Durnam, and D Przepiorka, and J O'Quigley, and J Sanders, and K M Sullivan, and R P Witherspoon, and H J Deeg
Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants.
November 1989, Blood,
P J Martin, and J A Hansen, and B Torok-Storb, and D Durnam, and D Przepiorka, and J O'Quigley, and J Sanders, and K M Sullivan, and R P Witherspoon, and H J Deeg
Suppressive activity in recipients of non-T cell-depleted allogeneic bone marrow transplants: role of T cell-depleted syngeneic marrow.
December 1989, Bone marrow transplantation,
P J Martin, and J A Hansen, and B Torok-Storb, and D Durnam, and D Przepiorka, and J O'Quigley, and J Sanders, and K M Sullivan, and R P Witherspoon, and H J Deeg
Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms.
November 1989, Blood,
P J Martin, and J A Hansen, and B Torok-Storb, and D Durnam, and D Przepiorka, and J O'Quigley, and J Sanders, and K M Sullivan, and R P Witherspoon, and H J Deeg
The use of HLA-non-identical T-cell-depleted marrow transplants for correction of severe combined immunodeficiency disease.
January 1989, Immunodeficiency reviews,
P J Martin, and J A Hansen, and B Torok-Storb, and D Durnam, and D Przepiorka, and J O'Quigley, and J Sanders, and K M Sullivan, and R P Witherspoon, and H J Deeg
Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation.
November 1996, Bone marrow transplantation,
Copied contents to your clipboard!